Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003 | MicrobiomeTrials← Back to trialsNCT06714006
Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2025-04-07Est. Completion: 2028-11
Enrollment target: 166 participants Locations- South Coast Renal, Brockway House, Level 1, Suite 8, 82-86 Queen Street,, Southport, Gold Coast, Australia
- Concord Repatriation General Hospital, Concord, New South Wales, Australia
- Liverpool Hospital, Clinic G-Reception 133, Level 1, Clinical Building, Burnside Drive, Liverpool, New South Wales, Australia
- Sydney Adventist Hospital, Wahroonga, New South Wales, Australia
- Westmead Hospital, Clinical Research Unit, Level 6, B Wing/Building, Hawkesbury Road, Westmead, New South Wales, Australia
- Mater Hospital Brisbane, South Brisbane, Queensland, Australia
- St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
- Sunshine Hospital, Western Centre for Health Research and Education, Level 3, 176-190 Furlong Road, Saint Albans, Victoria, Australia
- Linear Clinical Research, Joondalup, Western Australia, Australia
- Pacific Clinical Research Network Auckland, Takapuna, Auckland, New Zealand
Other microbiome trials you might be interested in
Kidney Diseases
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease and is caused by mutat…
Amiens, FranceEst. completion Jul 1, 2030
Polycystic Liver Disease
The purpose of the trial is to compare the effectiveness and safety of 2 treatment regimens of CAM2029 (given weekly or …
Rochester, United StatesEst. completion Feb 5, 2025